Aberdeen Group plc Grows Stock Holdings in Humana Inc. $HUM

Aberdeen Group plc lifted its stake in Humana Inc. (NYSE:HUM) by 30.8% in the second quarter, HoldingsChannel reports. The firm owned 172,161 shares of the insurance provider’s stock after acquiring an additional 40,492 shares during the quarter. Aberdeen Group plc’s holdings in Humana were worth $41,815,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Janney Montgomery Scott LLC purchased a new position in Humana in the first quarter valued at $1,309,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Humana by 16.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock valued at $300,728,000 after purchasing an additional 158,528 shares during the period. Focus Partners Wealth boosted its holdings in Humana by 104.2% in the first quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock valued at $1,701,000 after purchasing an additional 3,281 shares during the period. Envestnet Asset Management Inc. boosted its holdings in Humana by 2.4% in the first quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider’s stock valued at $33,256,000 after purchasing an additional 2,950 shares during the period. Finally, Circle Wealth Management LLC purchased a new position in Humana in the first quarter valued at $425,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Down 3.6%

HUM opened at $280.24 on Monday. The business’s 50-day simple moving average is $279.45 and its 200-day simple moving average is $258.04. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. Humana Inc. has a one year low of $206.87 and a one year high of $315.35. The stock has a market capitalization of $33.71 billion, a P/E ratio of 21.51, a price-to-earnings-growth ratio of 1.64 and a beta of 0.42.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The firm had revenue of $32.39 billion for the quarter, compared to analyst estimates of $31.85 billion. During the same quarter last year, the firm posted $6.96 EPS. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. Analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.3%. Humana’s payout ratio is 27.17%.

Analyst Ratings Changes

HUM has been the subject of a number of recent research reports. Guggenheim reiterated a “buy” rating on shares of Humana in a report on Friday, October 3rd. Evercore ISI began coverage on Humana in a report on Monday, September 22nd. They issued an “in-line” rating and a $295.00 target price for the company. Barclays decreased their price target on Humana from $315.00 to $245.00 and set an “equal weight” rating for the company in a report on Friday, October 3rd. Bank of America lifted their price target on Humana from $280.00 to $300.00 and gave the stock a “neutral” rating in a report on Friday. Finally, Wolfe Research lifted their price target on Humana from $283.00 to $313.00 and gave the stock an “outperform” rating in a report on Monday, October 6th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $298.83.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.